| 1 |
pyrazinamide
(670 times)
|
Pulmonary Medicine
(126 times)
|
TB (159 times)
RIF (120 times)
EMB (104 times)
|
1957 [Pyrazinamide (PZA) in the therapy of tuberculosis].
|
| 2 |
Pyrazoloacridine
(27 times)
|
Neoplasms
(15 times)
|
HPLC (2 times)
5-APZ (1 time)
AUC (1 time)
|
1995 Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
|
| 3 |
pyrazinoic acid
(7 times)
|
Physiology
(3 times)
|
PZG (3 times)
hURAT1 (1 time)
mURAT1 (1 time)
|
1976 Renal excretion of urate in mongrel and Dalmatian dogs: a micropuncture study.
|
| 4 |
pyrazinoate
(4 times)
|
Physiology
(4 times)
|
BBMV (1 time)
|
1985 Sodium-pyrazinoate cotransport in rabbit renal brush border membrane vesicles.
|
| 5 |
pyrazinecarboxylic acid
(2 times)
|
Biochemistry
(1 time)
|
BBMVs (1 time)
SUA (1 time)
|
2010 Identification and functional characterization of uric acid transporter Urat1 (Slc22a12) in rats.
|
| 6 |
(RIF)-pyrazinamide
(1 time)
|
Anti-Bacterial Agents
(1 time)
|
---
|
2009 Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
|
| 7 |
p-aminohippurate and pyrazinoate
(1 time)
|
Drug Therapy
(1 time)
|
---
|
1983 Effects of p-aminohippurate and pyrazinoate on the renal excretion of salicylate in the rat: a micropuncture study.
|
| 8 |
Pachymetric Zernike analyses
(1 time)
|
Ophthalmology
(1 time)
|
KC (1 time)
|
2015 A novel zernike application to differentiate between three-dimensional corneal thickness of normal corneas and corneas with keratoconus.
|
| 9 |
patients are resistant to pyrazinamide
(1 time)
|
Pulmonary Medicine
(1 time)
|
MR (2 times)
TB (1 time)
|
2012 Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec.
|
| 10 |
pentazolate anion
(1 time)
|
|
m-CPBA (1 time)
p-PZPol (1 time)
p-PZPolA (1 time)
|
2018 Roads to pentazolate anion: a theoretical insight.
|
| 11 |
peripheral zone sectional area
(1 time)
|
Neoplasms
(1 time)
|
CGA (1 time)
DCA (1 time)
MRI (1 time)
|
2021 MRI-Based Nomogram of Prostate Maximum Sectional Area and Its Zone Area for Prediction of Prostate Cancer.
|
| 12 |
phenotypic and genotypic pyrazinamide
(1 time)
|
Communicable Diseases
(1 time)
|
MDR (1 time)
TB (1 time)
XDR (1 time)
|
2016 Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations.
|
| 13 |
phenyl(1,3,5-triaza-7-phosphatricyclo(3.3.1.1(3,7))dec-6-yl)methanol
(1 time)
|
Chemistry
(1 time)
|
PTA (1 time)
PZA, 1 (1 time)
|
2007 Diastereomerically enriched analogues of the water-soluble phosphine PTA. Synthesis of phenyl(1,3,5-triaza-7-phosphatricyclo[3.3.1.1(3,7)]dec-6-yl)methanol (PZA) and the sulfide PZA(S) and X-ray crystal structures of the oxide PZA(O) and [Cp*IrCl(2)(PZA)].
|
| 14 |
Poricoic acid ZA
(1 time)
|
Complementary Therapies
(1 time)
|
Ang II (1 time)
EMT (1 time)
LPC (1 time)
|
2017 Poricoic acid ZA, a novel RAS inhibitor, attenuates tubulo-interstitial fibrosis and podocyte injury by inhibiting TGF-beta/Smad signaling pathway.
|
| 15 |
potent anti-tuberculosis drug combination pyrazinamide
(1 time)
|
Biomedical Engineering
(1 time)
|
CFZ (1 time)
EMB (1 time)
Mtb (1 time)
|
2020 Validation of a universal and highly sensitive two-dimensional liquid chromatography-tandem mass spectrometry methodology for the quantification of pyrazinamide, ethambutol, protionamide, and clofazimine in different biological matrices.
|
| 16 |
potent anticancer agent 9-methoxypyrazoloacridine
(1 time)
|
Biochemistry
(1 time)
|
---
|
2005 Design, synthesis, and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cells.
|
| 17 |
Prettau Anterior Zirkonzahn
(1 time)
|
Dentistry
(1 time)
|
BFS (1 time)
PZ (1 time)
TP (1 time)
|
2017 Effect of coloring and sintering on the translucency and biaxial strength of monolithic zirconia.
|
| 18 |
protizinic acid
(1 time)
|
Pharmacology
(1 time)
|
AA (1 time)
IM (1 time)
MZA (1 time)
|
1981 [Interaction of phenothiazinic anti-inflammatory agent, protizinic acid, with the biopolymers: Inhibitory effects on functions of platelets (author's transl)].
|
| 19 |
pyrazolylaniline
(1 time)
|
Biochemistry
(1 time)
|
PIN (1 time)
|
2017 Regioselective Synthesis of o-Benzenediboronic Acids via Ir-Catalyzed o-C-H Borylation Directed by a Pyrazolylaniline-Modified Boronyl Group.
|
| 20 |
PZase hydrolyses pyrazinamide
(1 time)
|
Biotechnology
(1 time)
|
PZase (1 time)
|
2003 An assessment of a multiplex PCR assay for differentiating clinically important mycobacteria based on pncA gene variation.
|
A Search Service for Abbreviation / Long Form